Durability And ScalabilityDurability emerges as the primary value driver, as sustained benefit, time-to-relapse, and redosing patterns will define clinical credibility, regulatory confidence, and long-term uptake.
Financial PerformanceSSR's Q3 adjusted EPS of $0.32 matched consensus expectations, and was ahead of our $0.20.
Operational SuccessSSR has a solid portfolio of operating assets in the Americas and a strong balance sheet.